Skip to main content

Table 2 Radiation parameters and treatment characteristics

From: Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases

ID

PTV (ml)

GTV (ml)

TD (Gy)

SD (Gy)

Fractions

Isodose

PTV-Dmax (Gy)

PTV-D2% (Gy)

PTV-D50% (Gy)

PTV-D98% (Gy)

GTV-D50% (Gy)

BED10

1

175.8

57.8

25.0

5.0

5.0

60%

42.8

42.3

37.7

29.0

41.3

37.5

2

376.0

225.5

25.0

5.0

5.0

60%

28.1

27.8

26.6

24.6

26.8

37.5

3

123.0

53.8

25.0

5.0

5.0

60%

41.8

41.7

39.6

29.7

41.1

37.5

4

45.0

x

25.0

5.0

5.0

60%

x

25.3

21.0

x

x

37.5

5

39.3

14.0

25.0

5.0

5.0

60%

42.0

41.5

34.5

26.3

39.1

37.5

6

37.3

8.3

35.0

7.0

5.0

65%

54.3

53.8

47.3

33.7

52.6

59.5

7a

40.7

12.9

40.0

8.0

5.0

65%

61.7

59.2

48.8

39.0

53.8

72.0

7b

24.1

6.9

40.0

8.0

5.0

65%

61.0

59.7

49.1

40.5

55.3

72.0

8

87.4

13.3

35.0

7.0

5.0

60%

47.1

46.3

40.4

22.8

44.5

59.5

9

71.9

21.0

25.0

5.0

5.0

60%

43.1

30.5

23.9

30.6

41.5

37.5

10

98.8

37.3

25.0

5.0

5.0

60%

x

25.5

23.3

x

24.6

37.5

11

69.8

25.6

40.0

8.0

5.0

65%

61.9

60.3

49.3

39.9

54.8

72.0

12

134.0

55.0

35.0

7.0

5.0

60%

x

37.7

31.9

x

34.0

59.5

13

122.2

51.3

35.0

7.0

5.0

60%

59.9

58.8

44.3

22.1

51.5

59.5

14

49.2

12.7

25.0

5.0

5.0

60%

41.9

41.9

38.6

30.1

41.0

37.5

15

82.8

33.0

25.0

5.0

5.0

80%

31.7

31.5

29.8

25.1

30.9

37.5

16

294.2

154.6

36.0

3.0

12.0

60%

62.7

59.2

47.6

33.3

50.6

46.8

17

434.8

247.5

27.0

5.4

5.0

60%

45.9

44.6

37.1

27.8

40.9

41.6

18

35.8

3.1

35.0

7.0

5.0

60%

61.8

60.8

47.6

31.9

58.9

59.5

19

81.6

22.3

35.0

7.0

5.0

60%

63.3

62.7

49.3

28.4

60.5

59.5

20

138.7

71.4

25.0

5.0

5.0

60%

39.5

37.7

26.3

25.3

27.6

37.5

21

58.5

12.2

35.0

7.0

5.0

60%

58.6

58.3

54.3

41.4

57.7

59.5

22

37.9

7.7

35.0

7.0

5.0

65%

56.0

54.8

43.2

24.9

50.7

59.5

23a

54.6

19.1

35.0

7.0

5.0

65%

55.9

55.3

46.7

35.8

53.2

59.5

23b

35.0

9.3

39.0

3.0

13.0

60%

68.2

67.0

50.3

36.4

62.7

50.7

24

25.1

4.2

36.0

3.0

12.0

60%

58.8

50.4

37.1

34.0

43.2

46.8

25

33.7

5.8

40.0

8.0

5.0

65%

63.4

61.9

50.3

41.1

57.5

72.0

26a

101.9

29.8

40.0

8.0

5.0

60%

70.7

69.4

54.6

29.6

66.6

72.0

26b

132.6

64.8

35.0

7.0

5.0

65%

55.5

54.7

51.6

38.4

53.8

59.5

27

71.6

17.1

40.0

8.0

5.0

60%

71.7

70.2

48.4

25.1

65.0

72.0

28

249.4

191.8

42.0*

3.0

14.0

60%

70.2

67.9

41.4

34.3

58.2

54.6

29

149.0

63.1

12.0*

4.0

3.0

60%

21.2

20.5

15.8

10.5

18.9

69.9

30

31.8

11.6

35.0

7.0

5.0

65%

53.9

52.1

43.8

35.7

46.9

59.5

31

78.8

27.8

40.0

8.0

5.0

65%

61.9

59.6

49.2

42.4

55.5

72.0

  1. *ID 28: 35 Gy á 2.5 Gy with simultaneous integrated boost on the adrenal lesion to a cumulative dose of 42 Gy á 3 Gy
  2. *ID 29: 45 Gy á 1.8 Gy with sequential boost on the adrenal lesion of 12 Gy á 4 Gy
  3. PTV planning target volume, GTV gross tumor volume, TD total dose, SD single dose